IL-23 Dependent and Independent Stages of Experimental Arthritis: No Clinical Effect of Therapeutic IL-23p19 Inhibition in Collagen-induced Arthritis

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Cornelissen, Ferry ^a   Asmawidjaja, Patrick S ^a   Mus, Adriana M C ^a   Corneth, Odilia ^a   Kikly, Kristine ^b   Lubberts, Erik ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 23 ANTIBODY; INTERLEUKIN 23P19; INTERLEUKIN 23P19 ANTIBODY; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; AREA UNDER THE CURVE; ARTHRITIS; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL ACTIVITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; GENE EXPRESSION; IMMUNOMODULATION; IN VIVO STUDY; MALE; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; TH1 CELL; TH17 CELL;

ANIMALS; ARTHRITIS, EXPERIMENTAL; BASE SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; COLLAGEN; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOLOGIC MEMORY; INTERLEUKIN-23; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; NEUTRALIZATION TESTS; POLYMERASE CHAIN REACTION;

EID: 84874554850     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057553     Document Type: Article

References (24)

1. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, et al. (2000) Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13: 715-725.
2. Croxford AL, Mair F, Becher B, (2012) IL-23: one cytokine in control of autoimmunity. Eur J Immunol 42: 2263-2273.
3. Parham C, Chirica M, Timans J, Vaisberg E, Travis M, et al. (2002) A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 168: 5699-5708.
4. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC,et al. (2006) Transforming growth factor-beta induces development of the T(H)17 lineage. Nature.
5. Kolls JK, Linden A, (2004) Interleukin-17 family members and inflammation. Immunity 21: 467-476.
6. Hunter CA, (2005) New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 5: 521-531.
7. Wiekowski MT, Leach MW, Evans EW, Sullivan L, Chen SC, et al. (2001) Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death. J Immunol 166: 7563-7570.
8. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, et al. (2003) Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 198: 1951-1957.
9. Yago T, Nanke Y, Kawamoto M, Furuya T, Kobashigawa T, et al. (2007) IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther 9: R96.
10. Yanaba K, Hamaguchi Y, Venturi GM, Steeber DA, St Clair EW, et al. (2007) B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. J Immunol 179: 1369-1380.
11. Krausz S, Boumans MJ, Gerlag DM, Lufkin J, van Kuijk AW, et al. (2012) Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis. Arthritis Rheum 64: 1750-1755.
12. Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, et al. (2004) Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 50: 650-659.
13. Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini IM, et al. (2010) LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 62: 929-939.
14. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, et al. (2010) Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2: 52ra72.
15. Gyulveszi G, Haak S, Becher B, (2009) IL-23-driven encephalo-tropism and Th17 polarization during CNS-inflammation in vivo. Eur J Immunol 39: 1864-1869.
16. McGeachy MJ, Chen Y, Tato CM, Laurence A, Joyce-Shaikh B, et al. (2009) The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol 10: 314-324.
17. Thakker P, Leach MW, Kuang W, Benoit SE, Leonard JP, et al. (2007) IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis. J Immunol 178: 2589-2598.
18. McGeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, et al. (2007) TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 8: 1390-1397.
19. Mus AM, Cornelissen F, Asmawidjaja PS, van Hamburg JP, Boon L, et al. (2010) Interleukin-23 promotes Th17 differentiation by inhibiting T-bet and FoxP3 and is required for elevation of interleukin-22, but not interleukin-21, in autoimmune experimental arthritis. Arthritis Rheum 62: 1043-1050.
20. Ghilardi N, Kljavin N, Chen Q, Lucas S, Gurney AL, et al. (2004) Compromised humoral and delayed-type hypersensitivity responses in IL-23-deficient mice. J Immunol 172: 2827-2833.
21. Lens JW, van den Berg WB, van de Putte LB, Berden JH, Lems SP, (1984) Flare-up of antigen-induced arthritis in mice after challenge with intravenous antigen: effects of pre-treatment with cobra venom factor and anti-lymphocyte serum. Clin Exp Immunol 57: 520-528.
22. Cornelissen F, Mus AM, Asmawidjaja PS, van Hamburg JP, Tocker J, et al. (2009) Interleukin-23 is critical for full-blown expression of a non-autoimmune destructive arthritis and regulates interleukin-17A and RORgammat in gammadelta T cells. Arthritis Res Ther 11: R194.
23. Lemos HP, Grespan R, Vieira SM, Cunha TM, Verri WA Jr, et al. (2009) Prostaglandin mediates IL-23/IL-17-induced neutrophil migration in inflammation by inhibiting IL-12 and IFNgamma production. Proc Natl Acad Sci U S A 106: 5954-5959.
24. Chen Y, Langrish CL, McKenzie B, Joyce-Shaikh B, Stumhofer JS, et al. (2006) Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 116: 1317-1326.